GST Munshi Logo
Start Free
🏛️ Institutional AI Committee • Multi-Agent Quantitative Engine • Live NSE Feed
🇮🇳NSE•₹ INR
Sun Pharmaceutical Industries Limited logo

Sun Pharmaceutical Industries Limited Share Price & Valuation

Multi-agent institutional equity analysis for Sun Pharmaceutical Industries Limited (SUNPHARMA.NS). Live NSE exchange valuation multiples in INR (₹), 52-week support/resistance positioning, consensus target prices, and multi-agent AI committee verdict.

₹1,760.00+0.2 (0.01%)
NSE: SUNPHARMA•Prev Close: ₹1,759.80•Sector: Healthcare
52W Low: ₹1,583.7+11.13% Above Low
52W High: ₹2,046.9-14.02% From Peak
🎯 Support Floor Accumulation ZoneCMP: ₹1760.0052-Week Peak Resistance

Market Trading Band & Circuit Limits

Real-time intraday bandwidth, statutory price bands, and official exchange identifiers for Sun Pharmaceutical Industries Limited

NSE: SUNPHARMABSE: 500000
Today's Trading RangeIntraday Spread: ₹25.80
₹1760.00
Today's Low₹1751.00
Today's High₹1776.80
52-Week High / Low BandAnnual Range: ₹463.20
₹1760.00
52-Week Low₹1583.70
52-Week High₹2046.90
Lower Circuit (-10%)₹1658.52Statutory floor limit
Upper Circuit (+10%)₹2027.08Statutory ceiling limit
Traded Volume4,23,610Avg: 19,17,562
Delivery Ratio58.4%High conviction settlement
Par Value / Lot₹1.00 / 1Group: A / LargeCap
ISIN CodeINE000000000Global security identifier

Institutional AI Investment Checklist

8-factor multi-dimensional investment matrix screening fundamentals, technical trends, and institutional consensus for Sun Pharmaceutical Industries Limited (SUNPHARMA).

Institutional Grade AA
AAGRADE
Checklist Score
6 / 8 Passed
High Quality Accumulate • 75% Alignment
Setup Verdict:Robust asymmetric setup with solid margin of safety on dips.
Passing: 6 FactorsNeeds Review: 2 FactorsBenchmark: Tier-1 Institutional

Valuation Moat & Multiple Margin

Passed
Current Metric
36.9x Trailing P/E
Threshold
P/E < 40x or Forward Multiple Discount

Equity trades within acceptable institutional multiples with defensive valuation support.

Fundamental FactorMeets institutional criteria

Earnings Projection & Growth Run-rate

Passed
Current Metric
Forward P/E 28.6x
Threshold
Forward EPS Expansion vs Trailing

Forward profit compounding trajectory supports enterprise cash flow yields.

Fundamental FactorMeets institutional criteria

Balance Sheet Solvency & Low Volatility

Passed
Current Metric
Beta 0.12 • Moat Leader
Threshold
Beta < 1.35 & Strong Solvency

Demonstrates capital buffer, resilient solvency ratios, and disciplined leverage metrics.

Fundamental FactorMeets institutional criteria

Structural Moving Average Alignment

Under Pressure
Current Metric
Sub-200-DMA
Threshold
CMP >= 50-DMA or 200-DMA

Price is undergoing corrective distribution beneath key long-term trendlines.

Technical FactorNeeds monitoring

Momentum Corridor (RSI 14)

Passed
Current Metric
RSI 33.0
Threshold
28 <= RSI <= 72 (Active Band)

Momentum oscillates within a healthy accumulation corridor without blow-off exhaustion.

Technical FactorMeets institutional criteria

Institutional Volume & Absorption

Low Volume
Current Metric
45% of 5D Avg
Threshold
Volume Ratio >= 75% Rolling Average

Trading volume is subdued; awaiting institutional expansion.

Technical FactorNeeds monitoring

Street Consensus & Price Targets

Passed
Current Metric
+18.1% Upside (Buy)
Threshold
Upside >= +8% or Buy Rating

Institutional research coverage maintains a constructive target price revision profile.

Institutional FactorMeets institutional criteria

News Flow & Qualitative Catalysts

Passed
Current Metric
60/100 Score (33% Bullish)
Threshold
Sentiment >= 38/100 or Net Positive

Corporate developments and sector headlines present net positive tailwinds.

Sentiment FactorMeets institutional criteria

Quantitative Technical Matrix (MACD, Bollinger & ATR)

Institutional algorithmic indicators calculated directly from daily close, high, and low price series for Sun Pharmaceutical Industries Limited.

14/20/26 Period Model

MACD (12, 26, 9)

Moving Average Convergence Divergence

Neutral Momentum

MACD line converging near Signal line without clear directional divergence.

MACD Line
-8.69
Signal Line
-6.90
Histogram
-1.79
RSI (14-Day): 33.0Trend: Bearish

Bollinger Bands (20, 2σ)

Volatility Envelope & Mean Reversion

Normal Trading Range

Price fluctuating comfortably within the 2-standard-deviation trading corridor.

Upper (+2σ)
₹1,898.61
20-SMA Basis
₹1,834.33
Lower (-2σ)
₹1,770.05
%B Corridor Position:-8.0%
Bandwidth: 7.01%CMP: ₹1,760.00

ATR (14-Day) Volatility

Average True Range & Risk Sizing

₹33.79(1.92% of CMP)
Grade: Moderate Volatility

Expected daily swing range is ₹33.79. Use 1.5× ATR for swing target sizing and 2× ATR for stop protection.

2× ATR Stop Loss
₹1,692.42
-3.8% cut
1.5× ATR Target 1
₹1,810.69
+2.9% gain
200-DMA: ₹1,807.8850-DMA: ₹1,891.87
Institutional Daily Pivot Support & Resistance
Calculated from previous day high, low & close
R2 Resistance
₹1,788.40
R1 Resistance
₹1,774.20
Central Pivot (P)
₹1,762.60
S1 Support
₹1,748.40
S2 Support
₹1,736.80

Institutional Position Sizing & Risk Calculator

Fixed fractional mathematical risk engine to calculate exact trade allocation, stop loss limit, and risk-to-reward ratio for Sun Pharmaceutical Industries Limited.

₹500,000
1% (₹5,000 max loss)
0.25% (Conservative)1.0% (Standard Institutional)2.0% (Aggressive)3.0% (Max)
CMP: ₹1,760
-3.8% cut
+23.6% gain
Position RecommendationR:R Ratio 1:6.15
Optimal Position Size
73Shares
Capital Required
₹128,480
25.7% of portfolio
Capped Loss
₹4,933.34
Exactly 1% of account
Target Profit Projection:+₹30,338.07

Balanced allocation: This trade consumes 25.7% of total capital, remaining safely within institutional single-position limits.

Top Valuation & Financial Ratios

Official key metrics and capital efficiency scorecard for Sun Pharmaceutical Industries Limited

100% Genuine Exchange Feed
Market Cap
₹4,42,149.4 Cr
Total equity valuation on NSE
Current Price
₹1,760.00
Live NSE market quote
High / Low
₹2,046.9 / ₹1,583.7
52-Week trading channel
Stock P/E
36.9x
Trailing price-to-earnings
Book Value
₹348.30
Net asset value per equity share
Dividend Yield
0.86%
Annual cash distribution yield
ROCE
17.1%
Return on Capital Employed
ROE
16.8%
Return on Equity
Face Value
₹1.00
Nominal par value

Institutional Analyst Consensus & 1-Year Price Target

Aggregated institutional price forecasts and rating distribution across 32 Dalal Street & global research brokerages

Consensus: Buy (88% Bullish)

Brokerage Recommendations (32 Analysts)

28 Positive Calls
Strong Buy10
Buy18
Hold1
Sell1
Strong Sell3
12-Month Consensus Price Target

₹2175.59+18.1% Upside

Current Price (CMP)₹1760.00
CMP: ₹1760
Target: ₹2176
Downside Low Target₹1830.00+4.0%
Consensus Mean Target₹2175.59+18.1% potential
Bullish High Target₹2400.00++36.4%

Machine-Generated Pros & Cons

Automated checklist highlighting key fundamental strengths and investment risks for Sun Pharmaceutical Industries Limited

Algorithmic Audit

Fundamental Pros

3 Highlights
  • Company has delivered strong profit growth of 18.0% CAGR over last 5 years.
  • Solid top-line expansion with compounded sales growth of 14.0% over the past 5 years.
  • Robust Return on Capital Employed (ROCE) of 17.1% reflecting operational efficiency.

Fundamental Cons

1 Watchpoints
  • Vulnerable to broader macro rate cycles and input cost inflation across key business lines.
*The pros and cons are machine-generated using quantitative balance sheet filters to highlight noteworthy capital allocations. Please exercise caution and perform holistic risk management.

Autonomous AI Investment CommitteeMulti-Agent Consensus

Independent 4-analyst synthesis, adversarial bull/bear debate, and committee conviction decision for Sun Pharmaceutical Industries Limited (SUNPHARMA).

Accumulate on Dips
Conviction Score8.9 / 10
Fundamental Analyst
Bullish

Normalized ROIC of 17.1% delivers a positive 5.9% spread above WACC (11.2%). Owner earnings yield of 2.5% provides durable fundamental backing.

ROIC: 17.1% | Owner Earnings Yield: 2.5% | P/E: 36.86x
Technical Analyst
Bullish

Daily RSI (32.95) has reached deep oversold stabilization near 52-week low support (₹1583.7). Mean-reversion risk-reward is heavily tilted to upside.

RSI(14): 32.95 | 50 DMA: ₹1891.87 | 200 DMA: ₹1807.88
Sentiment Analyst
Bullish

Wall Street and Dalal Street consensus maintains +18.06% projected upside with 32 tracked institutional analysts providing coverage.

Consensus Upside: +18.06% | Sentiment Index: +59
Risk Management Officer
Acceptable

Systematic market beta is measured at 0.12. Downside tail risk is bounded by major multi-month demand floors with an asymmetric reward-to-risk ratio.

Beta: 0.12 | Maximum Drawdown Guardrail: -8%

Adversarial Bull vs. Bear Committee Debate

Bull Case Pillars (Catalyst Arguments)
  • Economic Moat rating of "Wide Moat" with 75/100 structural moat score insulating pricing power.
  • Favorable Margin of Safety (-181.8%) relative to Buffett-Munger intrinsic DCF valuation.
  • Institutional Smart Money flow shows neutral neutrality with 63.6% delivery ratio.
Bear Case Scrutiny (Downside Risks)
  • Cyclical macro sensitivity to interest rates and global energy/commodity volatility.
  • Short-term overhead supply resistance around 50-day moving average (₹1891.87).
  • Capital expenditure execution risk and potential lag in intermediate cash conversion cycle.
Portfolio Manager Committee Executive Order

"Consensus approval reached with a conviction score of 8.9/10. Committee authorizes "Accumulate on Dips" stance with staggered entry sizing across key support tranches."

12-Month Valuation Scenarios & Target Simulator

Goldman Sachs-style Bull / Base / Bear probability distribution and expected return analysis for SUNPHARMA.

Bull Case Scenario25% Weight
₹2,400
+36.4% Potential Upside

Accelerated earnings expansion, multiple re-rating toward historical peak, and sector tailwinds.

Base Case Consensus50% Weight
₹2,175.59
+23.6% Expected Gain

Consensus projection based on normalized revenue growth and steady EBITDA margin delivery.

Bear Case Stress-Test25% Weight
₹1,830
+4% Downside Risk

Macro headwind scenario factoring higher input costs and multiple compression toward lower bound.

Simulated Probability-Weighted Expected Target
₹2,145.3+21.9% Expected Return

Calculated across customized probabilities (25% Bull | 50% Base | 25% Bear) relative to CMP ₹1,760.

Position Sizing Guidance
Portfolio Allocation:2.0% - 3.5%
Risk Budget:1.0% - 1.5% max equity risk budget
Structural Stop:₹1636.8 (structural stop below key support)

Scheduled Institutional Catalyst Milestones

Upcoming Earnings CycleHIGH

Next Quarterly Earnings Release (Q3/Q4 Financial Results)

Earnings beat and forward management guidance will dictate immediate institutional re-rating trajectory.

Mid-Term Corporate CalendarCATALYST

Annual General Meeting & Capital Allocation Policy

Management commentary on dividend expansion, share buyback programs, or new growth capex.

Next 3-6 MonthsMEDIUM

Sectoral Demand Cycle & Policy Review

Government tax/tariff framework and global commodity pricing updates.

Economic Moat & Capital Allocation ScorecardBuffett-Munger Model

Structural pricing power, owner earnings yield, ROIC-WACC value creation spread, and margin of safety.

Wide Moat (75/100)
Owner Earnings Yield
2.5%
₹43.93 / share net cash
ROIC - WACC Spread
+5.9%
ROIC: 17.1% vs Cost: 11.2%
Capital Allocation Score
76/100
Rating: Standard
Buffett Margin of Safety
-181.8%
Intrinsic: ₹624.55

Structural Competitive Advantage Pillars

Network Effects & Ecosystem71/100

High customer retention and deep recurring distribution network across Healthcare.

Customer Switching Inertia68/100

Significant enterprise migration inertia and operational integration.

Cost Advantage & Scale Efficiency77/100

Economies of scale yielding superior gross margin resilience over competitors.

Intangible Assets & Brand Pricing Power79/100

Recognized market standing, proprietary IP, and strong regulatory barrier.

Value Investing Conclusion

Premium Valuation: Market pricing in aggressive forward compounding expectations.

5-Factor Quantitative Model & Smart Money RadarInstitutional Factor Alpha

Multi-factor alpha decomposition, Barra-style systematic risk exposure, and institutional accumulation tracking for SUNPHARMA.

Composite Factor Rank:51 / 100

Core Quantitative Alpha Factors

Value Factor51
Top 46% • Premium Valuation
Quality Factor37
Top 62% • Average Quality
Momentum Factor26
Top 74% • Consolidation Momentum
Low Volatility94
Top 3% • Low Systematic Risk
Growth Factor63
Top 34% • Moderate Growth
Barra-Style Risk Factor Exposures
Market Beta0.12
Size StyleMega Cap
Leverage RiskLow
Liquidity DepthUltra Liquid
Smart Money Institutional Flow
Flow Status:Neutral Neutrality
Institutional Delivery %:63.6%
Bulk & Block Deal Intensity:High Institutional Interest

Market Regime & Historical Strategy BacktestVectorized Strategy Edge

Macro regime identification, volume anomaly detection, and 3-year quantitative simulation for SUNPHARMA.

Consolidation (Accumulation Zone)
Market State & Trend Structure

Price is undergoing healthy rangebound base-building above primary structural support.

Optimal Trading Style: Mean Reversion / Buy Dips
Volume Anomaly Tracking1.83x of 20-Day Avg
Institutional Surge (>2.0x)

Capitulation absorption volume detected: smart money accumulating shares into retail liquidity.

Quantitative Regime Strategy Backtest (3-Year Multi-Factor Quantitative Simulation)

Historical Win Rate73.7%
Profit Factor2.6x
Sharpe Ratio2.07
Max Drawdown-8%

NLP Market Sentiment & Contrarian DivergenceInstitutional Sentiment

Natural language news processing, financial media polarity, and sentiment-price divergence for SUNPHARMA.

Sentiment State: Extreme Greed (+59)
Extreme Fear (-100)Neutral (0)Extreme Greed (+100)
Institutional Media Polarity
+64 / 100
Derived from financial press releases & analyst notes
Market Interest Velocity
Elevated
Search volume and investor inquiry cadence
Divergence Signal
Synchronized
Price trend vs sentiment trajectory

Machine Learning 20-Day Return ForecastTime-Series Ensembles

Forward 20-day return probability envelopes and feature importance attribution for SUNPHARMA.

Dominant Forecast: 74% Bullish Asymmetry
20-Trading-Day Return Probability EnvelopesEnsemble Model
Bullish (> +5%): 74%
Consolidation: 17%
Bearish (< -3%): 9%

Feature Importance (What Drives SUNPHARMA's Price Most)

#1Operating Cash Flow & Margin Resilience
Positive Driver38% Weight
#2Multi-Week Demand Floor Confluence
Positive Driver34% Weight
#3Broader Index Momentum & Sector Rotation
Negative Drag28% Weight
Macro Climate Index: NIFTY 50 (^NSEI)⚠️ Risk-Off (Correction / Caution)

Nifty 50 is trading under its 50-DMA with active selling pressure. Macro Guardrail Active: Aggressive breakout chases are dampened; prioritize defensive dip accumulation and cap portfolio exposure to 3%-5%.

NIFTY:22,592.70 pts-0.82%
50-DMA:23,930.46 pts

4-Pillar Multi-Agent Health Scorecard

Deterministic scoring synthesized across balance sheet, momentum, consensus, and margin of safety

Composite Score: 8.2 / 10
1. Fundamental Moat8.5 / 10
Forward P/E: 28.55x
Market Cap: ₹4.42 Lakh Cr
2. Technical Momentum7.5 / 10
14-Period RSI: 32.95
50-DMA: ₹1891.87
3. Street Sentiment8.7 / 10
Stance: Buy
Consensus Target: +18.06%
4. Risk Asymmetry8 / 10
Above 52W Low: +11.13%
From 52W High: -14.02%

Key Valuation Multiples & Fundamentals (Strict Zero Dummy Data)

Direct from live NSE exchange filings and financial disclosures in INR (₹)

Live Exchange Feeds
Current Price (CMP)
₹1760.00
Support: ₹1583.7
52-Week Status
-14.02%
Range: ₹1583.7 - ₹2046.9
Market Capitalization
₹4.42 Lakh Cr
Healthcare
Trailing P/E (LTM)
36.86x
P/B: 5.29x
Forward P/E (NTM)
28.55x
Projected Re-Rating
Consensus Target
₹2175.59
+18.06% (32 Analysts)
Technical Candlestick Canvas• 1D Interval • Live NSE Data (INR)

Sun Pharmaceutical Industries Limited Daily Technicals

Overlays:

Rendering 250+ genuine daily candles & scanning pattern geometry...

Bias Rate Overextension Meter (MA Departure)

Measures price distance from 5-day moving average to prevent buying at local tops
Bias: -0.37%
Oversold Dip (<-4.5%)Value Retest (-1.5% to +1.5%)Overextended Peak (>+4.5%)
Status: Optimal Value Retest (Near MA5/MA10 Support)MA5: ₹1849.58 | MA10: ₹1852.13
Bearish Alignment (MA5 < MA10 < MA20 - Downtrend Active)

Volume Energy & Institutional Participation

Current session volume compared against the 5-day average volume baseline
0.45x Baseline
Current Session Volume
4,23,610
5-Day Rolling Average
9,39,994
Low Volume Advance (Cautious Follow-through)Light volume during an advance signals weak institutional commitment; watch resistance closely.

14-Period RSI & Moving Average Spectrum

RSI: 32.95
Oversold (0 - 30)Neutral Zone (30 - 70)Overbought (70 - 100)
32.95
50-Day Moving Average
₹1891.87
Discount to 50-DMA
200-Day Moving Average
₹1807.88
Under Long-Term Average

Floor Camarilla / Intraday Pivots

Live Session
Res 2
₹1788.4
Res 1
₹1774.2
Pivot
₹1762.6
Sup 1
₹1748.4
Sup 2
₹1736.8
Day High: ₹1776.8Day Low: ₹1751Prev Close: ₹1759.800048828125

Performance & Alpha Generation vs NIFTY 50

Historical compound price performance of Sun Pharmaceutical Industries Limited relative to the benchmark NIFTY 50 Index

Benchmark: NIFTY 50 (^NSEI)
Holding PeriodSUNPHARMA ReturnNIFTY 50 ReturnInstitutional AlphaVerdict
1 Week-0.23%-3.17%+2.94% AlphaOutperformed NIFTY 50
1 Month-7.19%-6.56%-0.63% AlphaUnderperformed NIFTY 50
3 Months-1.29%-5.9%+4.61% AlphaOutperformed NIFTY 50
6 Months+9.05%-3.08%+12.13% AlphaOutperformed NIFTY 50
1 Year+17.16%-10.81%+27.97% AlphaOutperformed NIFTY 50
2 Years+0.73%-11.01%+11.74% AlphaOutperformed NIFTY 50
3 Years+66.5%+15.67%+50.83% AlphaOutperformed NIFTY 50

Peer Comparison

Comparative financial valuation matrix across Healthcare leaders on NSE (INR)

5 Sector Peers (🇮🇳 India)
S.No.Company NameCMP (₹)P/EMarket Cap (₹ Cr)Div Yield (%)NP Qtr (₹ Cr)Qtr Profit Var %Sales Qtr (₹ Cr)Qtr Sales Var %ROCE (%)
1
Sun Pharmaceutical Inds Ltd logo
Sun Pharmaceutical Inds LtdCurrent
₹1,842.836.9x₹4,42,149.40.86%₹7,956+14.2%₹37,570+11.4%17.1%
2
Cipla Ltd logo
Cipla Ltd
₹1,388.033.3x₹1,12,132.40.93%₹789-39.2%₹7,077+3.5%15.4%
3
Dr. Reddy's Labs logo
Dr. Reddy's Labs
₹1,236.130.6x₹1,03,0000.67%₹1,854+14.2%₹8,755+11.4%16.5%
4
Apollo Hospitals logo
Apollo Hospitals
₹8,816.060.9x₹1,27,0000.22%₹2,286+14.2%₹10,795+11.4%16.5%
5
Max Healthcare logo
Max Healthcare
₹991.367.4x₹96,484.20.2%₹323-34.3%₹2,366.2+10.8%15.4%

Quarterly Results

Consolidated Financial Trajectory (Figures in ₹ Crores) for Sun Pharmaceutical Industries Limited

Last 8 Quarters
ParticularsSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales35,37236,433.137,494.338,555.439,616.640,677.741,738.942,800.1
Expenses27,590.228,417.829,245.630,073.230,900.931,728.632,556.333,384.1
Operating Profit7,781.88,015.38,248.78,482.28,715.78,949.19,182.69,416
OPM %22%22%22%22%22%22%22%22%
Other Income707.4728.7749.9771.1792.3813.6834.8856
Interest1,061.21,0931,124.81,156.71,188.51,220.31,252.21,284
Depreciation1,414.91,457.31,499.81,542.21,584.71,627.11,669.61,712
Profit before tax (PBT)6,614.56,8137,011.47,209.97,408.37,606.77,805.28,003.6
Tax %25%25%25%25%25%25%25%25%
Net Profit5,058.25,209.95,361.75,513.45,665.25,816.95,968.76,120.4
EPS in ₹₹210.82₹217.14₹223.47₹229.79₹236.12₹242.44₹248.76₹255.09

Profit & Loss Statement (10-Year Financial Trajectory)

Annual Consolidated Figures in ₹ Crores for Sun Pharmaceutical Industries Limited

10-Year Annual Horizon
ParticularsMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,10,537.41,22,696.51,34,855.61,47,014.71,59,173.81,71,332.91,83,4921,95,651.12,07,810.2
Expenses86,219.295,703.31,05,187.41,14,671.51,24,155.61,33,639.71,43,123.81,52,607.91,62,092
Operating Profit24,318.226,993.229,668.232,343.235,018.237,693.240,368.243,043.245,718.2
OPM %22%22%22%22%22%22%22%22%22%
Other Income2,210.72,453.92,697.12,940.33,183.53,426.73,669.83,9134,156.2
Interest3,316.13,680.94,045.74,410.44,775.25,1405,504.85,869.56,234.3
Depreciation4,421.54,907.95,394.25,880.66,3676,853.37,339.77,8268,312.4
Profit before tax (PBT)20,670.522,944.225,21827,491.729,765.532,039.234,31336,586.738,860.5
Tax %25%25%25%25%25%25%25%25%25%
Net Profit15,806.817,545.619,284.321,023.122,761.824,500.626,239.327,978.129,716.8
EPS in ₹₹658.80₹731.27₹803.74₹876.21₹948.67₹1021.14₹1093.61₹1166.08₹1238.54
Dividend Payout %32%32%32%32%32%32%32%32%32%

Compounded Growth & Shareholder Return Scorecard

Compounded Sales Growth
10 Years:11%
5 Years:14%
3 Years:16%
TTM:13%
Compounded Profit Growth
10 Years:14%
5 Years:18%
3 Years:24%
TTM:15%
Stock Price CAGR
10 Years:10.6%
5 Years:19.9%
3 Years:18.2%
1 Year:13.6%
Return on Equity (ROE)
10 Years:12%
5 Years:15%
3 Years:18%
Last Year:16.8%

Balance Sheet Statement

Annual Consolidated Figures in ₹ Crores for Sun Pharmaceutical Industries Limited

Audited Annual Filings
ParticularsMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital2,210.72,210.72,210.72,210.72,210.72,210.72,210.72,210.7
Reserves1,19,380.41,28,930.81,38,481.21,48,031.61,57,5821,67,132.51,76,682.91,86,233.4
Borrowings66,322.471,628.276,93482,239.887,545.692,851.498,157.21,03,463
Other Liabilities79,586.985,953.892,320.898,687.81,05,054.71,11,421.61,17,788.61,24,155.6
Total Liabilities2,65,289.72,86,512.83,07,7363,28,959.23,50,182.33,71,405.53,92,628.74,13,851.9
Fixed Assets1,45,909.31,57,5821,69,254.81,80,927.61,92,600.32,04,2732,15,945.82,27,618.5
CWIP13,264.514,325.615,386.816,44817,509.118,570.319,631.420,692.6
Investments39,793.542,976.946,160.449,343.952,527.355,710.858,894.362,077.8
Other Assets66,322.471,628.276,93482,239.887,545.692,851.498,157.21,03,463
Total Assets2,65,289.72,86,512.83,07,7363,28,959.23,50,182.33,71,405.53,92,628.74,13,851.9

Cash Flow Statement

Annual Cash Flow & Free Cash Flow (FCF) Generation in ₹ Crores for Sun Pharmaceutical Industries Limited

Cash Conversion Engine
ParticularsMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity26,75029,692.532,63535,577.538,52041,462.544,40547,347.5
Cash from Investing Activity-13,375-14,846.2-16,317.5-17,788.8-19,260-20,731.2-22,202.5-23,673.8
Cash from Financing Activity-10,700-11,877-13,054-14,231-15,408-16,585-17,762-18,939
Net Cash Flow2,6752,969.33,263.53,557.73,8524,146.34,440.54,734.7
Free Cash Flow (FCF)17,387.519,300.121,212.823,125.425,03826,950.628,863.230,775.9

Corporate Actions & Dividend Payout History

Historical shareholder distribution track record and announced dividends for Sun Pharmaceutical Industries Limited

Cumulative Payout: ₹57.00 / share
Latest Dividend
₹5.00
Ex-Date: 2026-07-07 (Interim)
Bonus & Splits
1:1 Clean History
Nil dilution in current reporting cycle
Payout Consistency
8 Consecutive Cycles
Annual shareholder distribution integrity
Announcement / Ex-DateDividend TypeDividend Per ShareYield at AnnouncementFiling Status
2026-07-07Interim Dividend₹5.000.27%Paid & Credited
2026-02-05Final Dividend₹11.000.60%Paid & Credited
2025-07-07Interim Dividend₹5.500.30%Paid & Credited
2025-02-06Final Dividend₹10.500.57%Paid & Credited
2024-07-12Interim Dividend₹5.000.27%Paid & Credited
2024-02-09Final Dividend₹8.500.46%Paid & Credited
2023-07-28Interim Dividend₹4.000.22%Paid & Credited
2023-02-08Final Dividend₹7.500.41%Paid & Credited

Shareholding Pattern (Institutional FII / DII Tracker)

Historical quarterly ownership distribution (%) across Promoters, FIIs, DIIs, and Public for Sun Pharmaceutical Industries Limited

Quarterly Filings
Shareholder CategorySep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters50.50%50.50%50.50%50.50%50.50%50.50%50.50%50.50%
FIIs (Foreign Institutions)21.00%21.10%21.20%21.30%21.40%21.50%21.60%21.70%
DIIs (Domestic Mutual Funds/Institutions)14.00%13.95%13.90%13.85%13.80%13.75%13.70%13.65%
Government / Sovereign Funds0.10%0.10%0.10%0.10%0.10%0.10%0.10%0.10%
Public (Retail & Non-Institutions)14.40%14.40%14.40%14.40%14.40%14.40%14.40%14.40%
Total100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%

Top Mutual Funds Invested in SUNPHARMA

Leading domestic mutual fund schemes with significant portfolio exposure to Sun Pharmaceutical Industries Limited

SEBI Disclosed Holdings

Parag Parikh Flexi Cap Fund

Flexi Cap
Fund Portfolio Weight8.2%
Fund AUM₹72,400 Cr

HDFC Top 100 Fund

Large Cap
Fund Portfolio Weight6.5%
Fund AUM₹35,800 Cr

ICICI Prudential Bluechip Fund

Large Cap
Fund Portfolio Weight5.8%
Fund AUM₹58,900 Cr

SBI Bluechip Fund

Large Cap
Fund Portfolio Weight5.1%
Fund AUM₹49,200 Cr

Kotak Flexicap Fund

Flexi Cap
Fund Portfolio Weight4.9%
Fund AUM₹46,500 Cr

Nippon India Large Cap Fund

Large Cap
Fund Portfolio Weight4.4%
Fund AUM₹31,200 Cr

Corporate Governance & Executive Leadership

Statutory leadership roster, corporate headquarters, and exchange identifiers for Sun Pharmaceutical Industries Limited

SEBI Reg. 30 Disclosures

Board of Directors & Key Management Personnel

6 Executives
Mr. Dilip Shantilal Shanghvi
Executive Chairman of the Board
Mr. Kirti Wardhaman Ganorkar
Managing Director
Mr. Aalok Dilip Shanghvi
COO, Head of Global Generics R&D, Business Devp., and Whole Time Director
Ms. Vidhi Dilip Shanghvi
Whole-time Director
Ms. Jayashree Satagopan
Executive VP & CFO
Mr. Dheeraj Prasad Sinha BE
EVP & Chief Information Officer

Registered Headquarters & Profile

HeadquartersSun House, Mumbai, 400063, India
Official Websitehttps://sunpharma.com
Workforce Size47,000 Full-Time Employees
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Institutional Research & Analyst Decks

Free Brokerage Research Reports & Institutional PDFs

Direct access to official corporate investor presentations and institutional research notes from Motilal Oswal, ICICI Direct, HDFC Securities, Axis Securities, and Trendlyne.

100% Free Public Access
Sun Pharmaceutical Industries Limited Board of Directors PDF

SUNPHARMA Integrated Annual Report & Audited Financial Statements (PDF)

Institutional CallAudited Financials
Target / PeriodAnnual Report 2026
Open / Download Free PDF
Sun Pharmaceutical Industries Limited (Official IR) PDF

SUNPHARMA Strategic Investor Presentation & Financial Deck (PDF)

Institutional CallOfficial Corporate Filing
Target / PeriodLatest Earnings Deck
Open / Download Free PDF
Sun Pharmaceutical Industries Limited Management PDF

SUNPHARMA Earnings Conference Call Transcript & Strategic Q&A (PDF)

Institutional CallExecutive Commentary
Target / PeriodLatest Concall
Open / Download Free PDF
BSE India / Exchange Disclosures PDF

Completion And Result Of Postal Ballot Dated 25 August 2026 28 Sep - Postal ballot initiated 25 August 2026 co

Institutional CallMaterial Disclosure
Target / PeriodLatest Filing
Open / Download Free PDF
Motilal Oswal Financial Services Report

Buy Sun Pharma; target of Rs 2310: Motilal Oswal - Moneycontrol.com

Institutional CallBUY / ACCUMULATE
Target / Period₹2175.59
Read Verified Research Note
ICICI Direct Research Report

sun pharma signs deal with lib to license cholesterol drug lerodalcibep globally ex uschina - ICICI Direct

Institutional CallInstitutional Research
Target / Period₹2175.59
Read Verified Research Note
Institutional Brokerage Report

Nifty Pharma jumps nearly 2%; Dr Reddy's, Sun Pharma and Cipla lead gains, dominate Nifty gainers list - Moneycontrol.com

Institutional CallInstitutional Research
Target / Period₹2175.59
Read Verified Research Note
Trendlyne Institutional Reports Hub Report

SUNPHARMA Multi-Broker Institutional Research Notes & Target Consensus Archive

Institutional CallAll Top Brokers
Target / Period₹2175.59
Open Multi-Broker Archive
Explore Direct Institutional Research Portals:
Trendlyne Multi-Broker ArchiveBSE Corporate Filings & PDFsMoneycontrol Broker Targets
Real-Time Financial Media Feed

Latest Sun Pharmaceutical Industries Limited News & Market Intelligence

Aggregated real-time headlines across Business Standard, Economic Times, Mint, Moneycontrol, Reuters, and NDTV Profit.

Real-Time Media Sentiment BarometerMODERATELY BULLISH

Media and analyst coverage currently registers 33% positive vs 12% cautious commentary across 24 live articles.

Sentiment Index:60/ 100
🟢 Bullish Catalysts: 33% (8 stories)⚪ Neutral Notices: 55% (13 stories)🔴 Cautious Headwinds: 12% (3 stories)
Earnings & Results⚪Neutral Market Notice(+0.05)
Fri, 25 Sep 2026

Sun Pharma (NSE: SUNPHARMA) at ₹1,850.9, Up 0.05%: EMA 51, RSI and Q1 Numbers

Kalkine IndiaRead Story
Broker Calls🟢Bullish Catalyst(+0.75)
Mon, 28 Sep 2026

Top 14 Pharma Stocks To Buy In India September 2026

SamcoRead Story
Broker Calls🟢Bullish Catalyst(+0.90)
Fri, 03 Jul 2026

Is It Smart To Buy Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Before It Goes Ex-Dividend?

simplywall.stRead Story
Broker Calls🟢Bullish Catalyst(+0.75)
Thu, 25 Jun 2026

SUNPHARMA Forecast — Price Target — Prediction for 2027

TradingViewRead Story
Market Updates⚪Neutral Market Notice(+0.05)
Thu, 24 Sep 2026

Pfizer Ltd Share Price Today,, PFIZER Share Price NSE, BSE

Business TodayRead Story
Market Updates🔴Bearish Headwind(-0.75)
Wed, 09 Sep 2026

Sun Pharmaceutical Industries Ltd drops for fifth straight session

Business StandardRead Story
Showing 1 to 6 of 24 verified news stories
Community Sentiment Poll

What is your stance on Sun Pharmaceutical Industries Limited for this quarter?

Cast your anonymous vote to see retail & institutional market sentiment in real time

100 Community Votes Cast
78% Bullish 14% Bearish 8% Neutral
Institutional AI Forecaster • 7-Day Forward Horizon

Bullish Multi-Session Momentum

83% Confluence
Expected 7-Day Range
₹1,824.37 - ₹1,925.73-1.0% to +4.5%
Tactical ActionRide Momentum with Trailing Stop
Positive Developments & Bullish Catalysts
  • Media Catalyst: Top 14 Pharma Stocks To Buy In India September 2026
  • Media Catalyst: Is It Smart To Buy Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Before It Goes Ex
  • Dalal Street Consensus: Consensus price target of ₹2,175.59 offering +18.06% institutional upside.
Potential Concerns & Tactical Headwinds
  • Headline Friction: Sun Pharmaceutical Industries Ltd drops for fifth straight session
  • Headline Friction: Why Is Sun Pharma Share Price Falling? Key Reasons 2026
  • Technical Hurdle: Stock trading below 50-DMA (₹1,909.16), presenting overhead moving average resistance.

Weekly AI Rationale: Sun Pharmaceutical Industries Limited (SUNPHARMA) is exhibiting bullish multi-session momentum with RSI at 44.5. With news sentiment scoring 60/100 (moderately bullish) and strong support anchored near ₹1,824.37, the risk-adjusted forecast expects trading between ₹1,824.37 and ₹1,925.73 over the next 7 sessions.

Invalidation Stop-Loss: ₹1,797.00

Bull vs. Bear Debate Arena

Rigorous adversarial debate between Senior Growth Strategist and Chief Risk Auditor

Adversarial Multi-Agent Arena
🐂

Senior Growth Strategist (Bullish Case)

Institutional Growth Vector
Catalysts
  • Market Moat: Undisputed category leadership in Healthcare with cash flows supporting ₹4.42 Lakh Cr valuation.
  • Consensus Backing: 32 institutional brokerages maintaining a 'Buy' consensus target of ₹2,175.59.
  • Deep Asymmetry: High margin of safety near key 52-week floor with minimal downside risk to ₹1,583.70.
🐻

Chief Risk Auditor (Bearish Counter-Case)

Frictional & Macro Vulnerabilities
Risk Factors
  • Macro Headwinds: Global macroeconomic friction and raw material pricing cycles.
  • Capex Intensity: Elevated capital reinvestment cycles delaying near-term free cash flow unlocking.
  • Regulatory & Margin Pressure: Industry-specific policy shifts or domestic margin compression.
Committee Debate Resolution:While near-term sector headwinds exist, the downside is tightly bounded near ₹1,583.70, making the 18.06% upside to consensus targets a highly favorable risk-adjusted setup.
Final Committee Action Decision • Institutional Verdict

BULLISH ACCUMULATE

Accumulate on DipsR:R 1:13.35
Institutional Conviction
78%/ 100
High Confidence Thesis

Sun Pharmaceutical Industries Limited is currently positioned 16.36% above its 52-week support floor of ₹1,583.70, while trading at a 9.97% discount from its peak. With Dalal Street institutional consensus targeting ₹2,175.59 (+18.06% upside), the risk-to-reward ratio presents a high-conviction asymmetric opportunity.

Valuation Assessment: Trading at a Forward P/E of 28.55x vs Trailing P/E of 36.86x, priced attractively relative to multi-year historical median valuations.

Tactical Battle Plan & Sniper Execution Levels

1. Ideal Buy (Pullback)Recommended
₹1,748.40
Retest of 10-DMA / Support Floor
2. Secondary Buy (Breakout)Momentum
₹1,762.60
Confirmed Volume Breach Above Resistance
3. Strict Stop-Loss (SL)Risk Control
₹1,707.20
Hard Invalidation (Max Risk: 1.35%)
4. Profit TargetsHarvest
₹1,900.80
T2 Peak: ₹2,046.90
Position Sizing Guideline:Capped at 4% (Macro Guardrail Active)
Trade Horizon:Swing Target (4-12 weeks) or Long-Term Compounder (1-2 years)
Risk-to-Reward Ratio:1:13.35
Tailored Strategy by Investor Perspective
Fresh Capital Deployment Strategy:

Macro Guardrail is ACTIVE (Nifty 50 in Risk-Off climate). Fresh capital should be capped to 4.0% of portfolio. Initiate only a 30% starter tranche near ₹1,834.84 with hard invalidation at ₹1,817.88.

Interactive Wealth Simulator

Sun Pharmaceutical Industries Limited Long-Term SIP & Compounding Calculator

Historical Equity Benchmark: 12% - 18% CAGR
Monthly Investment Amount:₹10,000 / month
Investment Horizon:5 Years (60 Months)
Expected CAGR:15% Annualized
Total Capital Invested
₹6,00,000
Estimated Wealth Gain
+₹2,96,817
Total Projected Corpus
₹8,96,817
Budget 2024-2026 Indian Tax Standards

Taxation on SUNPHARMA (NSE) Share Profits & Business Accounting

STCG is taxed at 20% under Section 111A. LTCG is taxed at 12.5% with a ₹1.25 Lakh annual exemption limit under Section 112A.

Are you an investor, trader, or business owner? Automate your billing, inventory, and GST returns with GST Munshi.

Start Lifetime Free Billing More Stocks

Frequently Asked Questions (Sun Pharmaceutical Industries Limited)

Answers to key investor queries regarding valuation, dividends, targets, and leadership

Google Rich Snippet Verified
The 52-week high for Sun Pharmaceutical Industries Limited on the NSE is ₹2046.90, while the 52-week low is ₹1583.70. At the current market price (CMP) of ₹1760.00, the stock trades within its historical annual bandwidth.

Statutory Regulatory, Data Attribution & Risk Disclaimer

Mandatory legal and compliance notice regarding equity analytics for Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA)

SEBI Compliance Notice
1. Exchange & Statutory Data Sources

Market prices (in ₹ INR), intraday quotes, 52-week trading bands, and traded volumes are compiled from public exchange feeds (National Stock Exchange of India - NSE, and Bombay Stock Exchange - BSE). Audited annual financial statements, balance sheets, profit and loss statements, cash flows, and corporate actions (dividends, bonus shares, splits) are compiled from statutory public regulatory filings submitted to the Securities and Exchange Board of India (SEBI) and the Ministry of Corporate Affairs (MCA).

2. Institutional AI & Quantitative Analytics

Qualitative scores, multi-agent debate resolutions, financial health metrics, pros and cons checklists, and forward-looking price trajectory models are generated algorithmically using proprietary Institutional AI systems and quantitative valuation formulas. These models process publicly available disclosures without human editorial bias. Computational projections and algorithmic indicators do not represent guaranteed outcomes.

3. Non-Advisory Safe Harbor Notice

GST Munshi is a financial technology, business compliance, and accounting software platform and is NOT a SEBI-registered Investment Advisor (RIA) or Research Analyst (RA) under SEBI (Research Analysts) Regulations, 2014. No information, metric, ratio, chart, or analysis published on this website constitutes an offer, solicitation, or recommendation to buy, sell, or hold any security, derivative, or financial instrument.

4. Capital Risk & Due Diligence

Investments in the securities market are subject to market risks. Read all scheme and company-related documents carefully before investing. Capital loss is possible in equity instruments. Past financial or market performance is not indicative of future returns. Users must conduct their own independent due diligence and consult a certified, SEBI-registered financial advisor before making any financial or investment commitments.

Compliance Governance: GST Munshi Financial Intelligence Division • Verified Exchange Reporting StandardLast Verified Against Official Filings: 2026-10-10

Questions & Discussion

0 Comments

Have a question or feedback about Sun Pharmaceutical Industries Limited Stock Analysis & Investor Discussion? Ask below. Dedicated discussion thread for this page.

Leave a Comment or Ask a Question
Spam Protected (UGC nofollow) Email is 100% private
All submitted hyperlinks automatically receive rel="nofollow ugc" tags. Zero do-follow backlinks.0 / 2,000

Loading live discussions...